Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
- PMID: 29021322
- PMCID: PMC5760457
- DOI: 10.1161/CIRCULATIONAHA.117.030848
Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control
Abstract
Background: In individuals with a low diastolic blood pressure (DBP), the potential benefits or risks of intensive systolic blood pressure (SBP) lowering are unclear.
Methods: SPRINT (Systolic Blood Pressure Intervention Trial) was a randomized controlled trial that compared the effects of intensive (target <120 mm Hg) and standard (target <140 mm Hg) SBP control in 9361 older adults with high blood pressure at increased risk of cardiovascular disease. The primary outcome was a composite of cardiovascular disease events. All-cause death and incident chronic kidney disease were secondary outcomes. This post hoc analysis examined whether the effects of the SBP intervention differed by baseline DBP.
Results: Mean baseline SBP and DBP were 139.7±15.6 and 78.1±11.9 mm Hg, respectively. Regardless of the randomized treatment, baseline DBP had a U-shaped association with the hazard of the primary cardiovascular disease outcome. However, the effects of the intensive SBP intervention on the primary outcome were not influenced by baseline DBP level (P for interaction=0.83). The primary outcome hazard ratio for intensive versus standard treatment was 0.78 (95% confidence interval, 0.57-1.07) in the lowest DBP quintile (mean baseline DBP, 61±5 mm Hg) and 0.74 (95% confidence interval, 0.61-0.90) in the upper 4 DBP quintiles (mean baseline DBP, 82±9 mm Hg), with an interaction P value of 0.78. Results were similar for all-cause death and kidney events.
Conclusions: Low baseline DBP was associated with increased risk of cardiovascular disease events, but there was no evidence that the benefit of the intensive SBP lowering differed by baseline DBP.
Clinical trial registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01206062.
Keywords: blood pressure; hypertension; randomized controlled trial.
© 2017 American Heart Association, Inc.
Figures
Comment in
-
Benefits and Risks of Antihypertensive Treatment: How Far Can Diastolic Blood Pressure Be Lowered?Circulation. 2018 Jan 9;137(2):144-147. doi: 10.1161/CIRCULATIONAHA.117.031370. Circulation. 2018. PMID: 29311347 No abstract available.
-
Letter by Stavropoulos et al Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control".Circulation. 2018 Jun 12;137(24):2664-2665. doi: 10.1161/CIRCULATIONAHA.117.032605. Circulation. 2018. PMID: 29891626 No abstract available.
-
Letter by Rahman and McEvoy Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control".Circulation. 2018 Jun 12;137(24):2666-2667. doi: 10.1161/CIRCULATIONAHA.118.033590. Circulation. 2018. PMID: 29891627 No abstract available.
-
Response by Beddhu et al to Letters Regarding Article, "Influence of Baseline Diastolic Blood Pressure on Effects of Intensive Compared With Standard Blood Pressure Control".Circulation. 2018 Jun 12;137(24):2668-2669. doi: 10.1161/CIRCULATIONAHA.118.034738. Circulation. 2018. PMID: 29891628 Free PMC article. No abstract available.
References
-
- Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899–1911. - PMC - PubMed
-
- Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903–1913. - PubMed
-
- Klag MJ, Whelton PK, Randall BL, Neaton JD, Brancati FL, Ford CE, Shulman NB, Stamler J. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334:13–18. - PubMed
-
- Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C. Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med. 2005;165:923–928. - PubMed
-
- Murakami Y, Hozawa A, Okamura T, Ueshima H. Relation of Blood Pressure and All-Cause Mortality in 180 000 Japanese Participants. Hypertension. 2008;51:1483. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
- UL1 TR000433/TR/NCATS NIH HHS/United States
- UL1 TR000445/TR/NCATS NIH HHS/United States
- UL1 TR000075/TR/NCATS NIH HHS/United States
- UL1 TR000093/TR/NCATS NIH HHS/United States
- UL1 TR000050/TR/NCATS NIH HHS/United States
- R01 DK091437/DK/NIDDK NIH HHS/United States
- HHSN268200900048C/HL/NHLBI NIH HHS/United States
- UL1 TR000005/TR/NCATS NIH HHS/United States
- HHSN268200900040C/HL/NHLBI NIH HHS/United States
- HHSN268200900046C/HL/NHLBI NIH HHS/United States
- UL1 TR000064/TR/NCATS NIH HHS/United States
- UL1 RR025764/RR/NCRR NIH HHS/United States
- P30 GM103337/GM/NIGMS NIH HHS/United States
- UL1 TR001064/TR/NCATS NIH HHS/United States
- UL1 RR025752/RR/NCRR NIH HHS/United States
- UL1 RR025771/RR/NCRR NIH HHS/United States
- HHSN268200900049C/HL/NHLBI NIH HHS/United States
- HHSN268200900047C/HL/NHLBI NIH HHS/United States
- UL1 TR001427/TR/NCATS NIH HHS/United States
- UL1 TR000003/TR/NCATS NIH HHS/United States
- UL1 TR000439/TR/NCATS NIH HHS/United States
- UL1 TR000073/TR/NCATS NIH HHS/United States
- C06 RR011234/RR/NCRR NIH HHS/United States
- UL1 RR025755/RR/NCRR NIH HHS/United States
- UL1 TR002003/TR/NCATS NIH HHS/United States
- UL1 TR000002/TR/NCATS NIH HHS/United States
- UL1 TR002240/TR/NCATS NIH HHS/United States
- UL1 TR000105/TR/NCATS NIH HHS/United States
- UL1 RR024134/RR/NCRR NIH HHS/United States
- R21 DK106574/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
